avastin
Novartis right to challenge NHS on Avastin use – ABPI chief
April 27, 2012Sales and Marketing ABPI, Lucentis, Whitehead, avastin, wet AMD
The ABPI has declared its support for Novartis in its legal challenge against off-label prescribing in England.The pharma company is …
GMC won’t relax off-label prescribing guidelines
April 25, 2012Sales and Marketing GMC, Lucentis, Novartis, Roche, avastin, off label, off-label
The GMC has decided not to relax guidelines on off-label prescribing when a licensed alternative exists. The GMC’s current rules …
Charity challenges government on Avastin for wet AMD
April 24, 2012Sales and Marketing Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD
A leading patient group has called on the government to get to grips with the issue of off-label prescribing, as …
Government to speed up access to new cancer drugs
April 24, 2012Sales and Marketing CDF, Cancer, Roche, UK, avastin, government, sha
Access to England’s Cancer Drugs Fund will be speeded up, ministers have confirmed. Currently, it can take a number of …
NICE rejects Avastin for breast cancer
April 18, 2012Sales and Marketing EMA, NICE, Roche, avastin, breast cancer
In a blow for Roche, NICE has turned down its cancer drug Avastin because of ‘too many uncertainties’ over cost …
Access to new cancer drugs limited in Brazil and Mexico
April 13, 2012Sales and Marketing Brazil, Cancer, Mexico, avastin, emerging markets
Between one-quarter and one-third of patients in Brazil and Mexico who are eligible for treatment with new cancer drugs do …
GMC guidance on off-label drug use delayed
March 19, 2012Sales and Marketing GMC, Lucentis, avastin, off label, off-label, prescribing
The General Medical Council has delayed the release of new guidance for off-label prescribing. The doctors’ regulator was expected to …
Major new drugs for 2012
March 9, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Caprelsa, Eylea, Manjor new drugs, Xalkori, Zelboraf, avastin, inlyta
Renal cell carcinoma Pfizer’s Inlyta (axitinib) has been approved as second line treatment for renal cell carcinoma. The drug is …
Avastin now available in UK for ovarian cancer
January 17, 2012Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Roche, avastin
Roche’s Avastin is now available as a treatment for women with ovarian cancer in the UK. Avastin (bevacizumab) can now …
Avastin gains EU licence for ovarian cancer
January 3, 2012Sales and Marketing Roche, avastin, ovarian
Roche’s Avastin has been granted a new European licence to treat ovarian cancer, which could help offset falling sales of …
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
FDA pulls Roche’s Avastin for breast cancer
November 21, 2011Research and Development, Sales and Marketing FDA, Roche, avastin
The FDA has pulled Avastin’s breast cancer licence in the US after the drug failed to prove its safety and …
FDA’s rejection of Avastin creates conflict
October 31, 2011Research and Development, Sales and Marketing FDA, avastin, breast cancer
Oncology experts have expressed concern at the FDA’s rejection of Roche’s Avastin for the treatment of advanced breast cancer. A …
NHS regions back Avastin for eye disease
October 14, 2011Sales and Marketing avastin
Regional NHS authorities around England are approving the use of Avastin instead of Lucentis for ophthalmology patients. A number of …
